好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical and Economic Impact and Treatment Patterns in People With Secondary Progressive Multiple Sclerosis: A Retrospective Cohort Study in the United States
Multiple Sclerosis
P2 - Poster Session 2 (11:45 AM-12:45 PM)
20-002
To evaluate the real-world clinical and economic impact and treatment patterns in people with secondary progressive multiple sclerosis (SPMS) in the United States (US).

SPMS is characterized by insidious disability accumulation, with or without relapses. The evidence on SPMS-related clinical and economic burden, and its treatment patterns is limited.

A retrospective cohort study was conducted using a US-claims database from 01/01/2018 to 06/30/2023. Adult people diagnosed with SPMS were required to be enrolled in a health plan throughout the 2-year observation period. Baseline demographics, comorbidities, healthcare resource utilization (HCRU), healthcare costs (HCCs; adjusted to 2023 US-dollars), and treatment patterns were analyzed descriptively.
The study included 4,587 people with SPMS (mean±standard deviation [SD] age, 57.8±10.1 years; female, 76.9%; commercially insured, 73.5%). The mean±SD Charlson Comorbidity Index score was 2.0±2.4, while infections were reported in 80.5% of people with SPMS. The top three most common MS-related comorbidities were abnormal gait (63.9%), malaise/fatigue (54.7%), and depression (37.2%).  The mean±SD Kurtzke Functional Systems adapted disability score was 4.7±1.9. During the observation period, all-cause hospitalizations were recorded in 30.9% of the cohort, while 44.8% had an emergency department visit. Occupational and physical therapies were received by 71.2% and 62.8% of people with SPMS, respectively, while 68.3% required ambulatory devices. The total mean all-cause HCCs was $168,895, primarily attributable to the costs of medical claims ($97,590) and outpatient pharmacy claims ($71,306). At baseline, 2,938 (64.1%) people with SPMS were on disease-modifying therapy (DMT) and 1,569 (34.2%) were not on any DMT. The top 3 most common observed DMTs during the observation period were ocrelizumab (22.8%), glatiramer acetate (10.0%), & dimethyl fumarate (9.2%).
People with SPMS exhibit a high clinical and economic burden, underscoring the need for more effective treatments in this population with limited therapeutic options currently indicated primarily for active SPMS.
Authors/Disclosures
Lita Araujo, PhD (Sanofi Genzyme)
PRESENTER 		Dr. Araujo has received personal compensation for serving as an employee of Sanofi Genzyme.
Nupur Greene Nupur Greene has nothing to disclose.
MANAV DAS, MBBS Dr. DAS has nothing to disclose.
Joshua Chang, MD, PhD Dr. Chang has nothing to disclose.
Marian H. Tarbox Ms. Tarbox has nothing to disclose.
Michael Broder, MD Dr. Broder has received personal compensation for serving as an employee of ADVI Health. Dr. Broder has received personal compensation for serving as an employee of PHAR.